Technical Analysis for CRIS - Curis, Inc.

Grade Last Price % Change Price Change
grade C 1.43 4.38% 0.06
CRIS closed up 4.38 percent on Friday, March 22, 2019, on 51 percent of normal volume.

Earnings due: Mar 25

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical CRIS trend table...

Date Alert Name Type % Chg
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Earnings Movers Other 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 4.38%
Mar 21 Calm After Storm Range Contraction 4.38%
Mar 21 Wide Bands Range Expansion 4.38%
Mar 21 Overbought Stochastic Strength 4.38%
Mar 20 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.62%
Mar 20 Upper Bollinger Band Walk Strength 3.62%
Mar 20 Wide Bands Range Expansion 3.62%

Older signals for CRIS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Curis, Inc. engages in the research, development, and commercialization of cancer therapeutics. Its principal product is Erivedge capsule for treatment of adults with basal cell carcinoma (BCC) that has spread to other parts of the body or that has come back after surgery. The company also develops Erivedge, which is in phase II clinical trial for the treatment of operable nodular BCC; CUDC-427, a small molecule that has completed phase I clinical trial to promote cancer cell death in breast cancer and other solid tumors, and hematological cancers; and CUDC-907, a small molecule, which is in phase I clinical trial for the treatment of advanced lymphoma and multiple myeloma. In addition, it develops CUDC-101 that has completed phase I dose escalation clinical trial for the treatment of refractory solid tumors; and phase I expansion trial for the treatment of breast, gastric, head and neck, liver, or non-small cell lung cancers. Further, the company develops Debio 0932 that is in phase Ib expansion study for the treatment of solid tumors; and in a phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. It has collaborations with Genentech, Inc. for the development of Erivedge; and Debiopharm S.A. for the development and commercialization of Debio 0932. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Cancer Drugs Surgery Solid Tumors Drug Discovery Breast Cancer Multiple Myeloma Cancer Therapeutics Hematological Cancers Phosphoinositide 3 Kinase Inhibitor Protein Kinase Inhibitors Advanced Non Small Cell Lung Cancer Refractory Solid Tumors
Is CRIS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.55
52 Week Low 0.6
Average Volume 211,032
200-Day Moving Average 1.456
50-Day Moving Average 1.154
20-Day Moving Average 1.2225
10-Day Moving Average 1.351
Average True Range 0.1007
ADX 22.0
+DI 23.9906
-DI 14.6172
Chandelier Exit (Long, 3 ATRs ) 1.2079
Chandelier Exit (Short, 3 ATRs ) 1.3221
Upper Bollinger Band 1.5358
Lower Bollinger Band 0.9092
Percent B (%b) 0.83
BandWidth 51.255624
MACD Line 0.0891
MACD Signal Line 0.0662
MACD Histogram 0.0228
Fundamentals Value
Market Cap 205.75 Million
Num Shares 144 Million
EPS -0.50
Price-to-Earnings (P/E) Ratio -2.86
Price-to-Sales 27.52
Price-to-Book 24.84
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.55
Resistance 3 (R3) 1.54 1.49 1.53
Resistance 2 (R2) 1.49 1.46 1.50 1.52
Resistance 1 (R1) 1.46 1.44 1.48 1.47 1.52
Pivot Point 1.41 1.41 1.42 1.42 1.41
Support 1 (S1) 1.38 1.38 1.40 1.39 1.34
Support 2 (S2) 1.33 1.36 1.34 1.34
Support 3 (S3) 1.30 1.33 1.33
Support 4 (S4) 1.31